It has a much lower antigenicity compared to similar collagen-based bioinks because if its arginine-glycine-aspartic acid (RGD) peptide sequence. This tripeptide sequence promotes cellular growth increasing cellular viability when cells are incorporated.
GelMA contains matrix metalloproteinase (MMP) degradable motifs, enzyme binding locations that trigger the catabolism of the gelatin architecture in GelMA. The degradation of GelMA is then replaced by the natural ECM without triggering severe inflammatory response.
GelMA contains a gelatin protein base derived from naturally occurring sources. This is unlike other bioinks like Matrigel® where the base is derived from cancer cells which increases instability of the bioink and potentially exposes encapsulated cells to cancerous genetic material.